Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhythm BiosciencesFRA:0RY +1.09%31 Cash Ratio is 1.83 as of Dec. 2025, which is 66% below its 10-year median of 5.44. GuruFocus rates FRA:0RY with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, Rhythm Biosciences ranks better than 70.19% on this metric.
Rhythm Biosciences has a Cash Ratio of 1.83. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Rhythm Biosciences's Cash Ratio or its related term are showing as below:
FRA:0RY'
s Cash Ratio Range Over the Past 10 Years
Min: 0.69 Med: 5.44 Max: 73.89
Current: 1.83
During the past 8 years, Rhythm Biosciences's highest Cash Ratio was 73.89. The lowest was 0.69. And the median was 5.44.
FRA:0RY's Cash Ratio is ranked better than 70.19% of 208
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.945
vs FRA:0RY: 1.83
Rhythm Biosciences (FRA:0RY) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Rhythm Biosciences Cash Ratio Related Terms
Rhythm Biosciences Cash Ratio Historical Data
* Premium members only.
The historical data trend for Rhythm Biosciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Rhythm Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Biosciences Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Rhythm Biosciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Biosciences (FRA:0RY) has a Cash Ratio of 1.83 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Rhythm Biosciences and its competitors. This is 66% below median its historical median of 5.44. Over the past decade, Rhythm Biosciences' Cash Ratio has ranged from 0.69 to 73.89. According to the industry distribution chart, Rhythm Biosciences ranks #62 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 29.8%.
Is Rhythm Biosciences' Cash Ratio too high?
Rhythm Biosciences' current Cash Ratio of 1.83 is 66% below median its 10-year median of 5.44. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 73.89. The Medical Diagnostics & Research industry median Cash Ratio is 0.95. Rhythm Biosciences' value of 1.83 is 93.7% above this industry median. Based on the distribution chart, Rhythm Biosciences ranks #62 out of 208 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Rhythm Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' Cash Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Rhythm Biosciences ranks #62 out of 208 companies for Cash Ratio. This puts Rhythm Biosciences in the upper half of its industry. The industry median Cash Ratio is 0.95. Rhythm Biosciences' value of 1.83 is 93.7% above this benchmark. Historically, Rhythm Biosciences' own Cash Ratio has ranged from 0.69 to 73.89 over the past decade. While the company's 10-year median is 5.44 vs. the industry median of 0.95, Rhythm Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 0.95, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhythm Biosciences's current Cash Ratio of 1.83 is 93.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Rhythm Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Biosciences's current Cash Ratio is 1.83, which is 66% below median its own 10-year median of 5.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current Cash Ratio of 1.83. The current Cash Ratio is 1.83, which is 66% below median its 10-year median of 5.44 and 93.7% above the Medical Diagnostics & Research industry median of 0.95. Rhythm Biosciences' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current Cash Ratio is 1.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
31GF Score
Get the complete analysis for FRA:0RY
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0RY has been successfully added to your 
